Summary.-The serum of athymic nude mice bearing rat tumour xenografts has been examined for tumour-specific antigen. With a sarcoma and a hepatoma, tumourspecific antigen expression continued in xenograft growths, and sera of tumourbearing mice contained free antigen, assayed by its ability to neutralise reactivity of tumour-immune rat sera against tumour target cells in an indirect membraneimmunofluorescence test. In contrast, no anti-rat antibody was detectable in sera of mice bearing the xenografts, or rejecting cells injected in admixture with BCG.
IMMUNOSUPPRESSED and congenitally athymic (nude) mice are becoming widely used to study the growth of malignant xenografts, particularly human tumours, and to assess their responses to chemotherapy (Houghton et al., 1977; Povlsen & Jacobsen, 1975; Kopper & Steel, 1975; Lamerton & Steel, 1975; Sonis et al., 1977) , radiotherapy (Davy et al., 1977) and immunotherapy (Pimm & Baldwin, 1978) and to examine their growth kinetics (Pickard et al., 1975; Houghton & Taylor, 1978a; Lamerton & Steel, 1975) , karyotypes (Reeves & Houghton, 1978) and metabolism (Houghton & Taylor, 1978b) .
It is clearly important to establish that tumours growing as xenografts retain fundamental characteristics expressed in the primary donor or, in the case of experimental tumours, on syngeneic transplantation. In this context, human tumour xenografts have been shown to continue the production of several tumour-associated materials. For example, xenografts of Burkitt's lymphoma produce IgM (Povlsen et al., 1973) colon carcinomas produce CEA (Mach et al., 1974; Houghton & Taylor, 1978b) , and breast carcinoma produces calcitonin (Coombes et al., 1975 (Baldwin & Pimm, 1971 ) and hepatoma D23 by oral administration of 4-dimethylaminoazobenzene (Baldwin & Barker, 1967a) . These tumours have been maintained by routine s.c. trocar grafts in syngeneic recipients. Both possess individually distinct neoantigens, demonstrable by in vivo transplant-rejection reactions and in vitro by indirect membrane-immunofluorescence reactions with syngeneic tumour-immune rat sera (Baldwin & Pimm, 1971; Baldwin & Barker 1967a, b) .
For the present studies, in vitro culture lines were established in Eagle's medium supplemented with 10% calf serum and routinely harvested in 0-2500 trypsin, washed and suspended in Hanks' Solution.
Growth of xenografts.-Tumour growths wvere initiated by subcutaneous injection in the right flank of cells harvested from tissue culture. In some cases mice received one or two injections of cells in direct admixture with 500 tg moist weight of BCG organisms (Glaxo Percutaneous Vaccine, B.P., Glaxo Laboratories, Greenford, Middlesex); these inocula wvere consistently rejected (Pimm & Baldwin, 1975) . Mice were bled by cardiac puncture under ether anaesthesia, blood clotted at room temperature and stored at +4°C for 18 h. Cellular contamination was removed from serum by centrifugation at 500 g for 15 min, and serum clarified by centrifugation at 1500 g for 30 min and stored at -20°C.
Preparation of antisera.-Hepatoma D23 and sarcoma Mc7-specific antisera -were raised in syngeneic WAB/Not rats by repeated s.c. implantation of 60Co y-irradiated (15,000 rad) tumour tissue (Baldwin & Barker, 1967b) .
Allogeneic, anti-WAB/Not sera was raised in KX/Not rats by repeated implantation of viable D23 tumour tissue, these grafts being consistently rejected.
Mouse anti-rat serum was raised in heterozygous CBA nu/+ mice by i.p. injections of viable rat sarcoma Mc7 cells, these being consistently rejected.
Assay for antibody.-Rat tumour cells were harvested from tissue culture or prepared by trypsin digestion of solid xenograft growths from athymic mice (Baldwin & Barker, 1967b) . 2 x 106-5 x 106 cells were incubated for 20 min at room temperature w%Aith 0-1 ml serum, washed x 4 in Hanks' solution and resuspended in 01 ml of fluorescein-labelled antiglobulin, incubated for a further 20 min, washed x 4 in Hanks' solution and finally suspended in 1:1 (v/v) glycerol:phosphatebuffered saline (pH 7.2). For tests wAith rat antisera, normal rat serum was used as a negative control, and the fluorescent antiserum was rabbit anti-rat IgG, (Table II) . In no case was a significant reaction detected, using sera from mice with 24-46-day-old growths (Pimm & Baldwin, 1975) and the mice were subsequently tested for anti-rat antibody by the MIF reaction. Some mice received 2 injections of cells and BCG, at 30-day inter-vals. The sera from none of these groups of mice had antibody detectable by the MIF reaction (Table III) but again sera from heterozygous mice, rejecting tumour cells alone, reacted strongly. Detection of tumour-specific antigen in the serum of xenograft-bearing mice
The sera of athymic mice bearing xenografts were assayed for antigen by their ability to neutralize the reaction of rat tumour-immuine antisera against appropriate target cells in the MIF test. The results of these assays (Table IV) (Povlsen et al., 1973) , human colon-tumour xenografts produce characteristic epithelial mucin (Houghton & Taylor, 1978b) CEA and AFP, these latter demonstrable both within the xenograft and free in the host serum (Mach et al., 1974; Houghton & Taylor, 1978b; Miwa et al., 1977) . Similarly, a choriocarcinoma synthesized HCG (Kamneya et al., 1976) , and human mammary carcinomas continue to produce calcitonin (Coombes et al., 1975) and tumourassociated glycolipid (absent from nonmalignant tissue) and shed this into the serum (Nordquist et al., 1978) . Similar studies with animal-tumour xenografts have demonstrated the synthesis of myeloma protein by a mouse plasmacytoma, insulin by a hamster pancreatic-islet-cell tumour, and SV40 T-antigen by SV40-transformed mouse, rat and rabbit cells (Freedman et al., 1976) . The objective of the present studies was to examine the continued production in xenografts of the unique cell-surface tumour-associated neoantigens of 2 carcinogen-induced rat tumours, and here it has been demonstrated that these antigens are expressed during xenograft growth. Moreover, free antigen, assayed by its ability to specifically neutralize tumour-specific antibody, was demonstrable in the serum of xenograft bearers. Antigen is similarly shed during growth of these tumours in syngeneic rats, but is then frequently complexed with tumourspecific antibody (Bowen & Baldwin, 1976; reviewed by Price & Baldwin, 1977) . Assays carried out in the present study were with sera of mice with large tumours (1-2 cm in diameter) and no attempt has yet been made to correlate the level of serum tumour antigen and tumour size. It is probable that the serum of tumour-bearing mice contains other rat tumour products in addition to tumourspecific antigen, including species-specific antigens, but assays for these have not been carried out.
The present tests were unable to detect antibody to tumour-specific antigens or rat species antigens in the serum of mice developing xenografts. These (Tevethia et al., 1977) although inoculation of polyoma virus evokes antibody to virus, detectable by haemagglutination inhibition (Stutman, 1975) . With human tumour xenografts, anti-human antibody was demonstrable in the serum of athymic mice with a Burkitt's lymphoma xenograft (Povlsen et al., 1973) by both an indirect membraneimmunofluorescence test similar to that used here, and by complement-dependent cytotoxicity. However, antibody against membrane-associated EBV virus was not demonstrable, and the precise antigenic components of the human cells in the athymic mice were unresolved. Similar studies with mice bearing xenografts of the human bladder carcinoma line T24 failed to detect antibody by the membrane-immunofluorescence test (Pimm & Baldwin, 1978) .
Essentially the present studies extend those of others who have demonstrated continued production or excretion of tumour-associated materials, showing that individually distinct tumour-specific components are also produced during xenograft growth. Taken as a whole, these studies indicate that many fundamental characteristics of malignant cells remain unchanged during xenograft development, strengthening the case that xenografts may be used as models for the assessment of therapeutic protocols and as a source of tumour tissue or antigen, and that the serum of tumour-bearing animals may be a suitable source of tumour products.
